CN113196405A - 测定多肽的脱酰胺和免疫原性的系统和方法 - Google Patents
测定多肽的脱酰胺和免疫原性的系统和方法 Download PDFInfo
- Publication number
- CN113196405A CN113196405A CN201980083369.4A CN201980083369A CN113196405A CN 113196405 A CN113196405 A CN 113196405A CN 201980083369 A CN201980083369 A CN 201980083369A CN 113196405 A CN113196405 A CN 113196405A
- Authority
- CN
- China
- Prior art keywords
- deamidation
- protein
- correlation
- asynchronous
- peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006240 deamidation Effects 0.000 title claims abstract description 101
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims description 99
- 230000005847 immunogenicity Effects 0.000 title description 18
- 229920001184 polypeptide Polymers 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 126
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 126
- 230000003595 spectral effect Effects 0.000 claims abstract description 123
- 230000001360 synchronised effect Effects 0.000 claims abstract description 45
- 238000009826 distribution Methods 0.000 claims abstract description 34
- 108010043958 Peptoids Proteins 0.000 claims abstract 18
- 238000004458 analytical method Methods 0.000 claims description 42
- 239000000523 sample Substances 0.000 claims description 41
- 238000010219 correlation analysis Methods 0.000 claims description 11
- 238000000386 microscopy Methods 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims 3
- 238000001228 spectrum Methods 0.000 abstract description 67
- 230000008646 thermal stress Effects 0.000 abstract description 44
- 230000035882 stress Effects 0.000 abstract description 10
- 238000004611 spectroscopical analysis Methods 0.000 abstract description 8
- 238000005100 correlation spectroscopy Methods 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 107
- 150000001408 amides Chemical class 0.000 description 50
- 238000005516 engineering process Methods 0.000 description 49
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 31
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 30
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 29
- 230000000875 corresponding effect Effects 0.000 description 29
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 25
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 23
- 235000009582 asparagine Nutrition 0.000 description 23
- 229960001230 asparagine Drugs 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 20
- 229960002885 histidine Drugs 0.000 description 20
- 230000002776 aggregation Effects 0.000 description 19
- 238000004220 aggregation Methods 0.000 description 19
- 235000018977 lysine Nutrition 0.000 description 19
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 18
- 239000004472 Lysine Substances 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 16
- 230000008859 change Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 235000003704 aspartic acid Nutrition 0.000 description 12
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 235000002374 tyrosine Nutrition 0.000 description 12
- 238000002329 infrared spectrum Methods 0.000 description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 230000006399 behavior Effects 0.000 description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 10
- 235000014304 histidine Nutrition 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 10
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- 125000003118 aryl group Chemical class 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000004891 communication Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000004481 post-translational protein modification Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 8
- 238000004590 computer program Methods 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000010183 spectrum analysis Methods 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 238000010835 comparative analysis Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000004845 protein aggregation Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
- 229940009098 aspartate Drugs 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 238000000701 chemical imaging Methods 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000013500 data storage Methods 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229960002317 succinimide Drugs 0.000 description 4
- 230000010512 thermal transition Effects 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000005314 correlation function Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003498 protein array Methods 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000013347 comparability assessment Methods 0.000 description 2
- 238000000205 computational method Methods 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- 238000002242 deionisation method Methods 0.000 description 2
- 238000013400 design of experiment Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- -1 Amino Chemical group 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001845 vibrational spectrum Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/20—Protein or domain folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Chemical & Material Sciences (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Molecular Biology (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Crystallography & Structural Chemistry (AREA)
- Signal Processing (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating Or Analyzing Materials Using Thermal Means (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862750022P | 2018-10-24 | 2018-10-24 | |
US62/750,022 | 2018-10-24 | ||
PCT/US2019/057856 WO2020086845A1 (en) | 2018-10-24 | 2019-10-24 | System and method for determining deamidation and immunogenicity of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113196405A true CN113196405A (zh) | 2021-07-30 |
Family
ID=70332078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980083369.4A Pending CN113196405A (zh) | 2018-10-24 | 2019-10-24 | 测定多肽的脱酰胺和免疫原性的系统和方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210391030A1 (de) |
EP (1) | EP3870193A4 (de) |
JP (1) | JP2022507014A (de) |
KR (1) | KR20210080456A (de) |
CN (1) | CN113196405A (de) |
AU (1) | AU2019364440A1 (de) |
CA (1) | CA3117339A1 (de) |
MX (1) | MX2021004657A (de) |
WO (1) | WO2020086845A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023159011A1 (en) * | 2022-02-15 | 2023-08-24 | Protein Dynamic Solutions, Inc. | Real-time bioburden and direct endotoxin screening |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268628B1 (en) * | 2007-04-13 | 2012-09-18 | University Of Puerto Rico | Method for determination of protein, peptide or peptoid aggregation, stability, and viability and system using the same |
CN104076115A (zh) * | 2014-06-26 | 2014-10-01 | 云南民族大学 | 基于峰强度识别能力的蛋白质二级质谱鉴定方法 |
WO2017127679A1 (en) * | 2016-01-21 | 2017-07-27 | Protein Dynamic Solutions Llc | Method and system for spectral data analysis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102592843B1 (ko) * | 2017-06-12 | 2023-10-20 | 프로틴 다이나믹 솔루션즈 인크. | 결정 및 결정화의 분석을 위한 방법 및 시스템 |
-
2019
- 2019-10-24 US US17/288,476 patent/US20210391030A1/en active Pending
- 2019-10-24 CA CA3117339A patent/CA3117339A1/en active Pending
- 2019-10-24 MX MX2021004657A patent/MX2021004657A/es unknown
- 2019-10-24 WO PCT/US2019/057856 patent/WO2020086845A1/en unknown
- 2019-10-24 JP JP2021522366A patent/JP2022507014A/ja active Pending
- 2019-10-24 KR KR1020217014963A patent/KR20210080456A/ko active Search and Examination
- 2019-10-24 EP EP19876745.1A patent/EP3870193A4/de active Pending
- 2019-10-24 AU AU2019364440A patent/AU2019364440A1/en not_active Abandoned
- 2019-10-24 CN CN201980083369.4A patent/CN113196405A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268628B1 (en) * | 2007-04-13 | 2012-09-18 | University Of Puerto Rico | Method for determination of protein, peptide or peptoid aggregation, stability, and viability and system using the same |
CN104076115A (zh) * | 2014-06-26 | 2014-10-01 | 云南民族大学 | 基于峰强度识别能力的蛋白质二级质谱鉴定方法 |
WO2017127679A1 (en) * | 2016-01-21 | 2017-07-27 | Protein Dynamic Solutions Llc | Method and system for spectral data analysis |
Non-Patent Citations (1)
Title |
---|
徐凤彩: "《基础生物化学》", vol. 1, 31 January 2001, 华南理工大学出版社, pages: 225 * |
Also Published As
Publication number | Publication date |
---|---|
EP3870193A1 (de) | 2021-09-01 |
MX2021004657A (es) | 2021-09-08 |
US20210391030A1 (en) | 2021-12-16 |
WO2020086845A1 (en) | 2020-04-30 |
EP3870193A4 (de) | 2022-07-20 |
JP2022507014A (ja) | 2022-01-18 |
AU2019364440A1 (en) | 2021-05-20 |
KR20210080456A (ko) | 2021-06-30 |
CA3117339A1 (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11626188B2 (en) | Method and system for spectral data analysis | |
Melnikov et al. | Deep learning for the precise peak detection in high-resolution LC–MS data | |
Kan et al. | ExMS2: an integrated solution for hydrogen–deuterium exchange mass spectrometry data analysis | |
Chatani et al. | Water molecular system dynamics associated with amyloidogenic nucleation as revealed by real time near infrared spectroscopy and aquaphotomics | |
Hageman et al. | A structural variant approach for establishing a detection limit in differential hydrogen exchange-mass spectrometry measurements | |
US20240019360A1 (en) | Method and system for analyst of crystals and crystallization | |
CN113196405A (zh) | 测定多肽的脱酰胺和免疫原性的系统和方法 | |
Ye et al. | Artificial Intelligence-based Amide-II Infrared Spectroscopy Simulation for Monitoring Protein Hydrogen Bonding Dynamics | |
Gurel et al. | Structural and functional analysis of CEX fractions collected from a novel avastin® biosimilar candidate and its innovator: a comparative study | |
Lin et al. | Characterization of higher order structural changes of a thermally stressed monoclonal antibody via mass spectrometry footprinting and other biophysical approaches | |
Santos | Advanced strategies and modes of implementation of in-situ Raman Spectroscopy in monitoring mammalian processes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |